ABT
The quarter: solid, not sleepy
Abbott’s first-quarter 2026 numbers showed the company still doing what big healthcare conglomerates do best: grind out steady growth while juggling a few moving pieces at once. GAAP diluted EPS came in at $0.61, while adjusted EPS was $1.15 — up 6% — which is the kind of result that won’t break the internet, but does keep the engine humming.
The Exact Sciences plot twist
The real headline is that Abbott has completed its acquisition of Exact Sciences. That’s a big deal because it pushes Abbott deeper into oncology diagnostics, one of those markets Wall Street loves because it’s large, growing, and full of recurring demand.
Think of it like Abbott didn’t just buy a new gadget; it bought itself a whole new aisle in the pharmacy.
Guidance got a little more interesting
For the full year, Abbott now sees comparable sales growth of 6.5% to 7.5%. It also expects adjusted diluted EPS of $5.38 to $5.58, and that range already includes about $0.20 of dilution from the Exact Sciences deal.
So yes, the acquisition costs a little in the near term. But the company is basically telling investors: “We’re absorbing the hit now so we can play bigger later.”
Why you should care
For investors, this is the classic Abbott mix: dependable core performance plus a strategic move that could reshape the growth story. If the Exact Sciences integration goes smoothly, the market may start valuing Abbott less like a sleepy defensive name and more like a healthcare platform with an extra growth gear.
Big picture: boring companies love to surprise people by making one very non-boring move.